À dramatic increase in recognition of disorders of mitochon-followed by immunoblotting to precisely define the defect at drial energy metabolism has been seen in the last decade (1,2). the enzyme and protein level. These disorders show diverse clinical symptoms ranging from Despite progress in the diagnostic approach, we experienced pure myopathy with lactic acidosis to severe multisystem that, in almost a quarter of the patients with evidently reduced disease with central nervous system involvement. Frequently, substrate oxidation in muscle mitochondria, these abnormalibiochemical defects of the pyruvate dehydrogenase complex, tjes could not be ascribed to a known defect in one of the or of one or more of the four multisubunit complexes of the mitochondrial enzymes. We hypothesized that, in at least part respiratory chain, have been demonstrated as underlying 0f category of patients, malfunctioning of one of the causes (1, 3), or they are associated with mutations in the transport mechanisms across the mitochondrial membranes mitochondrial genome (1, 2).
Biochemical investigations in patients suspected to have a may cause biochemical and clinical disorders. For adequate functioning of the mitochondrial energy pathrespiratory chain defect are commonly performed on skeletal way> metaboIkes which are d¡rectly inyolved in the process of muscle. They may involve measurement of substrate oxidation or oxygen consumption by intact mitochondria to obtain infor mation about the overall flux through the various parts of the mitochondrial energy metabolism. In case of an impaired flux, the different enzyme components of the respiratory chain and of the pyruvate dehydrogenase complex are measured, possibly ••%® v>-% : : , :
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